Edition:
United Kingdom

People: Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

19.36USD
23 Aug 2019
Change (% chg)

$-0.97 (-4.77%)
Prev Close
$20.33
Open
$20.30
Day's High
$20.34
Day's Low
$19.34
Volume
205,094
Avg. Vol
182,424
52-wk High
$36.12
52-wk Low
$16.97

Sheehy, Douglas 

Mr. Douglas T. Sheehy is General Counsel, Secretary of the company. Mr. Sheehy has served as our General Counsel and Secretary since April 2016. Prior to joining Aimmune, Mr. Sheehy served as Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Codexis, Inc., a protein engineering company that develops biocatalysts for the pharmaceutical and fine chemical industries, from February 2014 to April 2016, as Senior Vice President, General Counsel and Secretary from 2009 to February 2014 and as Vice President, General Counsel and Secretary from 2007 to 2009. Prior to Codexis, Mr. Sheehy spent five years in key legal roles at CV Therapeutics, Inc., a publicly-held biopharmaceutical company that was subsequently acquired by Gilead Sciences, Inc. in 2009. He began his legal career as a corporate attorney at Gunderson Dettmer LLP. Mr. Sheehy holds a B.A. in history from Dartmouth College and a J.D. from American University, where he was Editor-in-Chief of the American University Law Review.

Basic Compensation

Total Annual Compensation, USD 2,138,220
Restricted Stock Award, USD 1,107,280
Long-Term Incentive Plans, USD --
All Other, USD 2,000
Fiscal Year Total, USD 3,247,490

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Mark McDade

353,093

Jayson Dallas

9,246,510

Eric Bjerkholt

2,108,820

Mary Rozenman

--

Douglas Sheehy

3,247,490

Daniel Adelman

2,131,590
As Of  31 Dec 2018